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Abstract
Background. Thrombotic thrombocytopenic purpura
(TTP)andhaemolyticuraemicsyndrome(HUS)arethrom-
botic microangiopathies (TMAs). They are generally diag-
nosed and treated by plasmapheresis in the presence of
non-immune haemolytic anaemia and thrombocytopenia.
Yet, many individuals admitted in our hospital for athrom-
bocytopenic renal failure of unknown cause were reported
to have TMA as main lesion on kidney biopsies.
Methods. Speculating that this presentation is not uncom-
mon and that the underlying lesion might not be suspected
because of current diagnostic criteria, we determined its
prevalence and other accompanying features through a ret-
rospectivesingle-centrecohortof50caseswhereTMAhad
been identified histologically.
Results.Atpresentation,normalserumplateletswerecom-
mon (44%) but still accompanied by abnormal serum LDH
in most subjects. End-stage renal disease and mortality at
5 years were also high especially in the athrombocytopenic
group, but unrelated to the underlying aetiology of TMA.
Importantly, several subjects in both groups received and
apparently responded to plasmapheresis.
Conclusion. In the absence of thrombocytopenia, TMA
should still be contemplated when renal failure is associ-
ated with high serum LDH and its possible treatment with
plasmapheresis assessed through prospective trials.
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Introduction
Thrombotic microangiopathy (TMA) was identified ini-
tially as the lesion causing thrombotic thrombocy-
topenic purpura (TTP), which presents with non-immune
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haemolyticanaemia,thrombocytopeniaandtissuedysfunc-
tion [1], and was identified later on also as the lesion caus-
ing haemolytic uraemic syndrome (HUS), which resembles
TTP except for affecting the kidney predominantly [2]. Al-
though the pathogenic mechanisms of TTP appear to differ
fromthoseofHUS,itisstillcommonusagetoconsiderboth
disorders as the same entity, and ‘non-immune haemolytic
anaemia’ and ‘thrombocytopenia’ as main diagnostic
criteria [3,4].
On several occasions, colleagues in our Division have
reported identifying TMA lesions in athrombocytopenic
patients only after a kidney biopsy had been obtained for
renalfailureofunknownaetiology.Theyhavealsoreported
that even if the TMA lesions occurred in the absence of
underlying condition and were apparently plasmapheresis
responsive,haematologistsfrequentlyarguedthatthistreat-
ment was of unproven benefit when one of the diagnostic
criteria for TTP/HUS was missing.
Based on our colleagues’ experience, and considering
that plasmapheresis is a well-tolerated and effective treat-
ment for TTP/HUS [5,6], we became concerned that the
criteria used to diagnose these disorders might lead, in be-
ingtooexclusive,toundertreatmanyindividualswithactual
TMA lesions. This worry was justified further by studies in
which HUS was found to be associated with a worse renal
outcome than TTP [7–10].
Subjects and methods
To confirm that TMA lesions had often presented atyp-
ically in our centre, we analysed a 30-year retrospective
cohort who underwent kidney biopsies before 2007 and
were found to have intimal proliferation and/or endothe-
lial swelling with luminal fibrin deposition in arterial or
capillary beds but no signs of acute rejection, vasculitis
or extensive microthromboses. Subjects with progressive
systemic sclerosis, diarrhoeal HUS or bone marrow trans-
plantation were excluded since disseminated intravascular
coagulation and malignant hypertension appeared unlikely
in all cases.
Clinicaldatawereextractedfromchartsatbothpresenta-
tionsandatupto5yearsfollowingdiagnosisandregrouped
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for analyses according to variables such as platelet count
(PLT)atpresentation.Databetweenthe‘lowPLT’and‘nor-
mal PLT’ groups were analysed further by Fisher’s exact
tests and Kaplan–Meier survival analyses.
Results
Fifty subjects constituted the cohort. In all cases, TMA
affected arteriolar beds predominantly and were accompa-
nied by secondary mesangiolysis, wrinkling of capillary
basement membranes or double contour images. As seen in
Table 1 (columns 1–3), the subjects were relatively young
(46 years) with a majority of females (70%) and had
frequently no underlying condition (46%). As expected,
thrombocytopenia was found in only 56% but serum LDH
wasstillelevated inmost(mean619U/L).Whenthecohort
wasdividedaccordingtoPLT,themostimportantdifference
observed was the higher percentage of athrombocytopenic
subjects who required dialysis although it did not reach
statistical significance. Importantly, TMA lesions in the
absence of underlying condition were associated with sim-
ilar findings (columns 4–6) and were of equal occurrence
between the ‘low PLT’ and ‘normal PLT’ groups (columns
1–3).
The number of subjects for whom data were available
5 years post-diagnosis decreased to 34 because TMA le-
sions had been identified beyond 2002 or because of loss
to follow-up. Table 2 shows that the most striking long-
term outcome was a lower renal and patient survival in the
‘normal PLT’ group (columns 1–3) and that this outcome
wassimilarintheabsenceofunderlyingcondition(columns
4–6)althoughnostatisticaldifferencewasseenduetopopu-
lationsize.Plasmapheresisinitiatedatthetimeofdiagnosis
Table 1. Presenting characteristics of subjects with biopsy-proven TMA
All subjects No underlying causes
Columns (1) (2) (3) (4) (5) (6)
Subgroups Total ↓ PLT N PLT Total ↓ PLT N PLT
n subjects 50 28 22 23 13 10
Age (y) 46 ± 17 47 ± 18 44 ± 16 47 ± 19 46 ± 21 47 ± 16
Males (%) 30 32 27 39 38 40
No underlying causes (%) 46 46 45 100 100 100
Underlying cause (%) 54 54 55 0 0 0
Low Hb (%) 94 100 86 96 100 90
Mechanic haemolysis (%) 94 100 86 96 100 90
Low platelets (%) 56 100 0§ 56 100 0§
Low Hb and PLT (%) 56 100 0§ 56 100 0§
High LDH (%) 86 89 82 87 92 80
High creatinine (%) 90 93 86 100 100 100
D i a l y s i s ( % ) 5 04 35 96 56 27 0
Plasmapheresis (%) 58 61 55 78 87 70
Potential underlying causes included stage IV lupus nephritis (12%), mixed connective tissue disease with or without polymyositis (14%), drugs (14%),
cyclosporine(0%),neoplasias(6%),renaltransplantation(4%)andpregnancy(4%).Forthisstudyserumcreatinine>1.2mg/dL,Hb<120g/L(female)
or<140g/L(male),PLT<150×109/L andLDH>220U/Lwereconsideredabnormal(loworelevated).Mechanichaemolysiswasdefinedasfollows:
anaemia + low haptoglobin or high indirect bilirubin + negative Coomb’s test. In all cases, INR was < 1.26 and in no cases, abnormal serum D-dimers
or fibrinogen was found. Based on Fisher’s exact tests, values indicated by the § sign were significantly different statistically (P < 0.03) between the
‘low PLT’ and ‘normal PLT’ groups.
Table 2. Characteristics of subjects with biopsy-proven TMA 5 years after diagnosis
All subjects No underlying causes
Columns (1) (2) (3) (4) (5) (6)
Subgroups Total ↓ PLT N PLT Total ↓ PLT N PLT
All subjects (n) 3 41 8 1 6 1 79 8
↓ CR > 1.5 mg/dL (%) 12 17 6 24 22 13
E S R D ( % ) 5 04 4 5 6 6 55 6 7 5
Death (%) 18 6 31 6 0 13
ESRD or death (%) 68 50 88§ 71 56 88
Plasmapheresis (n)§ 23 14 9 13 8 5
No underlying causes (%) 56 57 56 100 100 100
↓ CR > 1.5 mg/dL (%) 17 21 11 31 38 20
E S R D ( % ) 4 84 3 5 6 5 45 0 6 0
Death (%) 17 7 33 8 0 20
ESRD or death (%) 65 50 89 62 50 80
§ = at the time of diagnosis, CR = serum creatinine and ESRD = end-stage renal disease. Cohort characteristics were similar to those reported in
Table 1 legend. Based on Fisher’s exact tests, values indicated by the § sign were significantly different statistically between the ‘low PLT’ and ‘normal
PLT’ groups (P < 0.03).1050 S. A. De Serres and P. Isenring
Fig.1. PatientsurvivalfollowinghistologicaldiagnosisofTMA.Basedon
a Kaplan–Meier analysis, curves were significantly different statistically
between the ‘low PLT’ and ‘normal PLT’ groups (P = 0.023).
appeared to offer no long-term benefit (compare %
between the ‘all subjects’ and ‘plasmapheresis-treated sub-
jects’groups)buttocorrelatewithlowerserumcreatinineat
1 year (not shown), suggesting that subjects lost to follow-
up subjects had better outcomes. The predictive value of
PLT at presentation is suggested further by lower 60-month
cumulative survival rates in the ‘normal PLT’ group
(Figure 1).
Discussion
This study highlights the usefulness of retrospective co-
horts to confirm clinical impressions acquired through per-
sonal experience and the importance of serum LDH or tis-
sue biopsies to identify atypical cases of TMA. Perhaps
in this regard, newer biological markers of TTP/HUS such
as serum levels of high molecular weight Von Willebrand
factors and ADAMTS-13 will also prove useful in the di-
agnosis of TMA when PLT is normal [10,11].
In contrast to statements that were made in the recent
articles [3,4], our study has shown that TMA lesions could
present with normal PLT and lead to substantial renal dam-
age quite commonly. These observations raise the con-
cern that athrombocytopenic TMA may not be consid-
ered for timely therapeutic interventions based on current
diagnostic criteria or because of delayed identification.
Theyshouldthusbeseenasanincentivetoconductprospec-
tive trials aimed at determining the usefulness of plasma-
pheresis in atypical forms of TMA.
Through consensus reports, a simplified clinical defini-
tion of TTP/HUS has been proposed in the 1990s [12]. In
our opinion, it did not rest on solid evidence and implied
that TMA was always easy to diagnose. This impression
is now supported by the current analysis and is in keeping
with newer concepts that have emerged from the molecu-
lar and clinical investigation of TTP/HUS. For instance, it
is now known that several pathogenic mechanisms are in-
volvedandthattheytendtodifferevenwhenmanifestations
are alike [13–15]. Whether idiopathic athrombocytopenic
TMAisauniqueentityinthisregardneedstobeconfirmed.
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